Fosun Pharma gets dual drug approvals for breast cancer, GI treatment

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the National Medical Products Administration for an additional indication for Fovinaciclib Citrate Capsules, a CDK4/6 inhibitor, and for Famotidine Injection. The Fovinaciclib Citrate Capsules, developed by its subsidiary Jinzhou Avanc Pharmaceutical Co., Ltd., are now approved for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine therapy. This adds to its existing approval for advanced or metastatic breast cancer. As of August 2025, the group has invested approximately RMB617 million in the R&D of Fovinaciclib Citrate Capsules.

Additionally, Jinzhou Avanc Pharmaceutical Co., Ltd. received approval for Famotidine Injection. This chemical drug is indicated for upper gastrointestinal bleeding caused by peptic ulcers and other erosive bleeding. The group’s investment in the R&D of Famotidine Injection totals approximately RMB7.67 million as of August 2025. These approvals are expected to bolster Fosun Pharma's market competitiveness and broaden treatment options for patients in China.